Eli Lilly to start rolling submission for obesity drug approval this year




  • In US
  • 2022-10-06 11:11:03Z
  • By Reuters
 

(Reuters) -Eli Lilly and Co said on Thursday it plans to start a rolling submission to the U.S. Food and Drug Administration (FDA) this year to get an approval for its obesity drug tirzepatide.

The data it will submit will include that from two late-stage trials, one of which is expected in April.

The FDA has also granted "Fast Track" designation for the drug to treat obesity or overweight with weight-related comorbidities in adults, under which the regulator expedites the review of medicines to treat serious conditions and fill an unmet medical need.

Obesity is a major health concern in the United States, with the disease estimated to have affected more than 40% of the population and cost nearly $173 billion annually, as per data from the Centers for Disease Control and Prevention.

Shares of Eli Lilly were up 1.4% in premarket trade.

The FDA had already approved tirzepatide, under the brand name Mounjaro, for the treatment of Type 2 diabetes in May.

The company in April had reported that the drug had achieved a goal of helping patients lose more than 20% of their weight in a late-stage clinical trial, prompting analysts to increase their peak sales estimate for the drug.

Wells Fargo analyst Mohit Bansal had then raised his estimate for tirzepatide's sale as an obesity drug to $7.5 billion from $4 billion earlier while expecting total sales of the drug's franchise hit $18 billion at peak.

Tirzepatide's competition currently is a drug by Novo Nordisk, which is sold as Ozempic for treatment of Type 2 diabetes and Wegovy for use against obesity.

(Reporting by Leroy Leo in Bengaluru; editing by Uttaresh.V)

COMMENTS

More Related News

Use of drugs for weight loss causes supply shortage
Use of drugs for weight loss causes supply shortage

Dramatic stories about weight loss using popular drugs are trending on social media. People who need the drugs for other health issues now face shortages.

FDA likely to end blanket ban on sexually active gay men donating blood
FDA likely to end blanket ban on sexually active gay men donating blood

Under current federal rules, men cannot donate blood if they have had sex with another man in the last three months.

FDA clears 1st fecal transplant treatment for gut infection
FDA clears 1st fecal transplant treatment for gut infection

U.S. officials have approved the first pharmaceutical-grade version of the so-called fecal transplant procedures that doctors have increasingly used against hard-to-treat intestinal infections. The Food and Drug Administration on Wednesday approved Rebyota for adults who have trouble fighting off infections with Clostridium difficile, commonly referred to as C. diff, a bacteria that causes nausea, cramping and diarrhea. For more than a decade, some U.S. doctors have used stool samples from healthy donors to treat the condition.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US